Our Vision
The CTN will take a leadership role in advancing the use of radiopharmaceuticals and optimizing the use of molecular imaging in clinical trials and dissemination into clinical practice.
Mission
Facilitate the effective use of molecular imaging in clinical trials through standardization, coordination, and education for drug development and regulatory approval.
The CTN updated their Strategic Plan in 2013 to reflect the evolving needs of the community and changes in clinical trials and the regulatory environment. Our key goals are to:
- Ensure high-quality PET and SPECT imaging in the conduct of drug development clinical trials
- Work towards use and approval of new radiopharmaceuticals
- Facilitate access to investigational PET radiopharmaceuticals for multicenter clinical trials
- Provide education and training for the use of molecular imaging in clinical research
- Expand the depth of leadership, committee membership, and possibly technical staff personnel